

Sales revenues for February 2019

Sofia, Bulgaria, March 6, 2019 - Sopharma AD (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that for February 2019 the Company recorded a decrease of sales revenues of 14% compared to the same month of 2018, including 38% decrease of domestic sales and an increase of 1% of export sales.

During the first two months of 2019 the revenues from sales of production increased by 1% compared to the same period of 2018, including 15% decrease in domestic sales and 13% increase of export sales.



Pelagia Viatcheva

Investor Relations Director,

Sopharma AD

Information about the company

Sopharma AD

85 years of tradition and modernity - modern production, European standards and quality of production, corporate and social responsibility.

Today Sopharma is the most successful Bulgarian company after privatization, as from 2000 years to today, the company realized 10 times growth in market capitalization and 25 times revenue growth. Over the past 10 years, Sopharma has been the first in revenue in the pharmaceutical sector in Bulgaria.

With 10 pharmaceutical plants in the country and the only ampoule factory in Bulgaria with 24,000 ampoules per hour, it produces 3 billion tablets, 20 million syrup forms, 210 generic products, 15 original formulas, 12 plant-based products and uses 1500 tons of medicinal plants in their products.

Sopharma AD has an active and key role in raising the standard of living in making people healthier, happier and protected. Sopharma is constantly investing in new technologies, innovations and research. We are creating a permanent and effective dialogue with all stakeholders in the pharmaceutical industry that contribute to improving the healthcare system.

The company produces active substances and medicinal products; conducts activities related to research, development and implementation in the field of phytochemistry, chemistry and pharmacy. Sopharma AD provides services related to production as well as other related services.



Sopharma Group

Sopharma Group is a vertically integrated healthcare business that operates in important sectors such as pharmaceuticals, hospital supplies, drug distribution (GDP standardized) and many others. Sopharma and its production subsidiaries have 12 pharmaceutical plants in Bulgaria, complying with EU requirements - GMP, a factory in Ukraine certified by local authorities.

Sofia, Bulgaria
5 Lachezar Stanchev Str.
Sopharma Business Towers, Tower A

www.sopharmagroup.com
tel: +359 (0) 2 4055 200; +359 (0) 8134 200
fax: +359 (0) 2 4055 141; +359 (0) 8134 141